Driving drug discovery: The fundamental role of academic labs

Science Translational Medicine

Volumn 2, Issue 30, 2010, Pages

  Silber, B Michael ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; MEVINOLIN; RITUXIMAB; SIMVASTATIN; SMALL INTERFERING RNA; TORCETRAPIB;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL LABORATORY; DEGENERATIVE DISEASE; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG FATALITY; DRUG INDICATION; DRUG INDUSTRY; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; DRUG TREATMENT FAILURE; DRUG USE; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; HUMAN; MULTIPLE SCLEROSIS; NONHUMAN; NOTE; PATIENT SAFETY; PRIORITY JOURNAL; PROCESS OPTIMIZATION; UNIVERSITY HOSPITAL;

ACADEMIC MEDICAL CENTERS; BIOMEDICAL RESEARCH; DRUG DISCOVERY; DRUG INDUSTRY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PHARMACEUTICAL PREPARATIONS; TECHNOLOGY, PHARMACEUTICAL; UNIVERSITIES;

EID: 77952984894     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3000169     Document Type: Note

References (28)

1. J. A. DiMasi, R. W. Hansen, H. G. Grabowski, L. Lasagna, Cost of innovation in the pharmaceutical industry. J. Health Econ. 10, 107-142 (1991).
2. S. N. Wiggins, The Cost of Developing a New Drug (Pharmaceutical Manufacturers Association, Washington, DC, 1987).
3. J. A. DiMasi, R. W. Hansen, H. G. Grabowski, The price of innovation: New estimates of drug development costs. J. Health Econ. 22, 151-185 (2003).
4. Office of Technology Assessment, U.S. Congress, Pharmaceutical R&D: Costs, Risks, and Rewards, OTA-H-522 (U.S. Government Printing Office, Washington, DC, 1993).
5. Lehman Brothers, Drug R&D costs, success rates, and emerging technologies (1997), in PAREXEL's Pharmaceutical R&D Statistical Sourcebook 2000 (Parexel International, Waltham, MA, 2000).
6. J. A. DiMasi, H. G. Grabowski, The cost of biopharmaceutical R&D: Is biotech different? Manage. Decis. Econ. 28, 469-479 (2007).
7. D. Schwartzman, Innovations in the Pharmaceutical Industry (Johns Hopkins Univ. Press, Baltimore, MD, 1976).
8. H. A. Clymer, in The Economics of Drug Innovation, J. D. Cooper, Ed. (American Univ., Washington, DC, 1970), pp. 109-124.
9. B. Munos, Lessons from 60 years of pharmaceutical innovation. Nat. Rev. Drug Discov. 8, 959-968 (2009).
10. B. M. Silber, keynote address presented at the AAPS Drug Discovery Strategies and Critical Issues for Clinical Candidate Selection Meeting, San Francisco, CA, 19 May 2008 (http://mediaserver.aapspharmaceutica.com/meetings/ DDS/Innovative-Preclinical-Strategies-to-Increasing-Productivity-in-Drug-R-D- Finding-Medicines.pdf).
11. M. S. Brown, J. L. Goldstein, Multivalent feedback regulation of HMG CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth. J. Lipid Res. 21, 505-517 (1980).
12. S. L. Hauser, E. Waubant, D. L. Arnold, T. Vollmer, J. Antel, R. J. Fox, A. Bar-Or, M. Panzara, N. Sarkar, S. Agarwal, A. Langer-Gould, C. H. SmithHERMES Trial Group, B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 358, 676-688 (2008). (Pubitemid 351240747)
13. N. J. Caplen, S. Parrish, F. Imani, A. Fire, R. A. Morgan, Specific inhibition of gene expression by small doublestranded RNAs in invertebrate and vertebrate systems. Proc. Natl. Acad. Sci. U.S.A. 98, 9742-9747 (2001).
14. G. Hutvágner, M. J. Simard, C. C. Mello, P. D. Zamore, Sequence-specific inhibition of small RNA function. PLoS Biol. 2, e98 (2004).
15. H. Song, S. K. Chung, Y. Xu, Modeling disease in human ESCs using an efficient BAC-based homologous recombination system. Cell Stem Cell 6, 80-89 (2010).
16. T. Vierbuchen, A. Ostermeier, Z. P. Pang, Y. Kokubu, T. C. Südhof, M. Wernig, Direct conversion of fi broblasts to functional neurons by defi ned factors. Nature 463, 1035-1041 (2010).
17. K. Takahashi, S. Yamanaka, Induction of pluripotent stem cells from mouse embryonic and adult fi broblast cultures by defined factors. Cell 126, 663-676 (2006).
18. A. J. Ivinson, R. Lane, P. C. May, D. A. Hosford, M. C. Carrillo, E. R. Siemers, Partnership between academia and industry for drug discovery in Alzheimer's disease. Alzheimers Dement. 4, 80-88 (2008).
19. S. L. Schreiber, Target-oriented and diversity-oriented organic synthesis in drug discovery. Science 287, 1964- 1969 (2000).
20. A. Shaginian, L. R. Whitby, S. Hong, I. Hwang, B. Farooqi, M. Searcey, J. Chen, P. K. Vogt, D. L. Boger, Design, synthesis, and evaluation of an ?-helix mimetic library targeting protein-protein interactions. J. Am. Chem. Soc. 131, 5564-5572 (2009).
21. M. A. Schmitt, B. Weisblum, S. H. Gellman, Unexpected relationships between structure and function in α, β-peptides: Antimicrobial foldamers with heterogeneous backbones. J. Am. Chem. Soc. 126, 6848-6849 (2004).
22. R. E. Becker, N. H. Greig, Alzheimer's disease drug development in 2008 and beyond: Problems and opportunities. Curr. Alzheimer Res. 5, 346-357 (2008).
23. E. Giacobini, R. E. Becker, One hundred years after the discovery of Alzheimer's disease. A turning point for therapy? J. Alzheimer's Dis. 12, 37-52 (2007).
24. S. B. Hendrix, G. K. Wilcock, What we have learned from the Myriad trials. J. Nutr. Health Aging 13, 362-364 (2009).
25. L. S. Schneider, D. K. Lahiri, The perils of Alzheimer's drug development. Curr. Alzheimer Res. 6, 77-78 (2009).
26. W. M. Pardridge, Alzheimer's disease drug development and the problem of the blood-brain barrier. Alzheimers Dement. 5, 427-432 (2009).
27. S. C. Johnston, S. L. Hauser, Can industry rescue the National Institutes of Health? Ann. Neurol. 60, A11-A14 (2006).
28. G. Tamgüney, K. P. Francis, K. Giles, A. Lemus, S. J. DeArmond, S. B. Prusiner, Measuring prions by bioluminescence imaging. Proc. Natl. Acad. Sci. U.S.A. 106, 15002- 15006 (2009).